Tezepelumab in severe uncontrolled asthma, evolution towards “disease modifying” therapy
COPD in exacerbation, prospects for new biological therapeutic interventions
it
Prof. Alberto Papi
Reducing the social impact of COPD with preventive diagnostic strategy
it
Prof. Paola Rogliani
The therapeutic scenario in severe asthma, between biological drugs and biosimilars
it
Prof. Giorgio Walter Canonica
Gender medicine in respiratory diseases and in the definition of care pathways
it
Prof. Elena Bargagli
Reimbursement of anti-smoking drugs is needed to combat the e-cigarette emergency
it
Dr. Roberto Boffi
COPD stability as a new therapeutic target
it
Prof. Fulvio Braido
Bronchial asthma: poor adherence to steroid therapy, what are the consequences?
it
Dr. Claudio Micheletto
Lung cancer screening with low-dose CT reduces mortality
it
Prof. Michele Mondoni
Progressive interstitial lung diseases: importance of early diagnosis and treatment
it
Prof. Paolo Spagnolo
State of the art in bronchiectasis management
it
Prof. Andrea Gramegna
Benralizumab in severe asthma: clinical remission exceeds three years
it
Dr. Paolo Cameli
Tezepelumab in severe uncontrolled asthma, evolution towards “disease modifying” therapy
it
Dr. Francesco Pelaia
Female and adolescent smoking: what strategies can be used to combat it?
it
Dr. Roberto Boffi
Biological drugs, new perspectives for use in eosinophilic COPD
it
Dr. Claudio Micheletto